Partnering / Partnering Opportunities

Assets available for co-development and licensing

Baliopharm is seeking for strategic partners to advance the development of its lead compounds.


The following products are available for partnering:
 

  1. The TNF-R1 specific antibodies Atrosab and Atrosimab for the treatment of

 i) Autoinflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and inflammatory bowel disease (M. Crohn and colitis ulcerosa)

ii) Chronic liver diseases such as Nonalcoholic steatohepatitis (NASH)

iii) Neuro-inflammatory and neuro-degenerative diseases like multiple sclerosis or Morbus Parkinson
 

  1. The bispecific antibody Novotarg for the treatment of

 i) Autoimmune diseases associated with B lymphocyte involvement, like multiple sclerosis (MS)

ii) B-cell malignancies, like chronic lymphocytic leukemia (CLL)

 

Baliopharm pursues to drive the further clinical development of Atrosab, Atrosimab and Novotarg in collaboration with a committed industry partner and is open for different collaboration scenarios such as co-development or licensing.

For further information, please contact:


Dr. Andreas Herrmann (CEO)
a.herrmann@baliopharm.com